Products

APTIOM^® (eslicarbazepine acetate) is indicated as:

Monotherapy in the management of partial-onset seizures in adult patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy.
Adjunctive therapy in the management of adults, and children above 6 years of age, with partial-onset seizures who are not satisfactorily controlled with conventional therapy.

CUBICIN^® (daptomycin for injection) is indicated for the following infections in adults:

Complicated skin and skin structure infections (cSSSI) caused by susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillinresistant strains), Streptococcus pyogenes and Streptococcus agalactiae.
Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains.

LATUDA^® (lurasidone HCl) is indicated:

for the management of the manifestations of schizophrenia.
as monotherapy or as adjunctive therapy with lithium or valproate for the acute management of depressive episodes associated with bipolar I disorder.